LobbyingRoyal Biologics lobbying by quarter
Royal Biologics's latest lobbying report covers Q1 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $70K. Its first report covers Q3 2025; the issues it reports most are Medicare/Medicaid.
Royal Biologics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $70K
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q3 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2025 | $40K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $20K | 1 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Medicare and Medicaid$110K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| The McManus Group | $110K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 04/20for Q1 | The McManus Group | $20K |
| 01/20for Q4 2025 | The McManus Group | $50K |
| 25/10/20for Q3 2025 | The McManus Group | $40K |
| 25/08/04for Q3 2025 | The McManus Group | Under $5,000 |